After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Armed with $75m the company takes a risky asset into the clinic.
The biotech licenses a China-developed anti-B7-H3 ADC.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
GEN1286 looks dead, though MCLA-129 continues for now.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
